TY - JOUR
T1 - Temporary Mechanical Circulatory Support and Shock Teams in High-Risk Cardiac Surgery
T2 - The Strategic Evolution of Protected Cardiac Surgery
AU - Salazar, Leonardo
AU - Nersesian, Gaik
AU - Meani, Paolo
AU - Bari, Gabor
AU - Mariani, Silvia
AU - Potapov, Evgenij
AU - Di Mauro, Michele
AU - Gelsomino, Sandro
AU - Milojevic, Milan
AU - Schmack, Bastian
AU - Stein, Louis
AU - Zimpfer, Daniel
AU - Wiedemann, Dominik
AU - Soltetz, Edward
AU - Bermudez, Christian
AU - Haft, Jonathan
AU - Moreno, Pedro
AU - Tonna, Joseph
AU - Takayama, Hiroo
AU - Lamarche, Yoan
AU - Rao, Vivek
AU - Faerber, Gloria
AU - Meyns, Bart
AU - Takeda, Koji
AU - Boeken, Udo
AU - MacLaren, Graeme
AU - Whitman, Glenn
AU - Patel, Bhavesh
AU - Silvestry, Scott
AU - Goldstein, Daniel J.
AU - Arora, Rakesh C.
AU - Engelman, Daniel T.
AU - Lorusso, Roberto
N1 - Funding Information:
Rakesh C. Arora reports receiving consulting fees for serving on advisory boards for Alexion, Renibus Therapeutics Inc, HLS Therapeutics Inc, and Edwards LifeSciences. Rakesh C. Arora reports participation as a DSMB member on the SCOPE Trial and IDMC member on the DECIDE Trial. Rakesh C. Arora reports being an Executive Board Member on ERAS Cardiac Surgery and Past President for the Canadian Society of Cardiac Surgeons. Rakesh C. Arora reports being the Chair of the STS Workforce on Critical Care. Daniel T. Engelman reports consulting fees from Edwards Lifesciences Transcatheter Valves for sitting on the Device Safety Monitoring Board. Daniel T. Engelman reports consulting fees from Alexion, Genentech, Bayer, and RenalGuard for sitting on research trial steering committees. Daniel T. Engelman reports consulting fees from Medela, Arthrex, Atricure, and Pharmacosmos for sitting on medical advisory boards. Roberto Lorusso reports receiving research grants from Medtronic and LivaNova. Roberto Lorusso reports receiving consulting fees from Medtronic, LivaNova, and J&J MedTech Heart Recovery (payments to the institution). Roberto Lorusso reports payment for lectures from Abiomed. Roberto Lorusso reports participation on advisory boards for Eurosets, Xenios, Hemocue and ChinaBridge Medical (payments to the institution). Roberto Lorusso reports leadership roles as ELSO Research Committee Chair, EuroELSO Honorary Secretary, and ESC Cardiovascular Surgery Working Group Nucleus Chair. Roberto Lorusso reports receiving ECMO-related material for animal experiments from Medtronic. Graeme MacLaren reports being the Past President of the Extracorporeal Life Support Organisation (ELSO). Bart Meyns reports receiving an institutional research grant from Abiomed J&J. Milan Milojevic reports a leadership position as Director of the Clinical Practice Guidelines Programme at the European Association for Cardio-Thoracic Surgery. Milan Milojevic reports receiving a speaker fee from Corcym in relation to ERAS. Bhavesh Patel reports holding stock from GE Healthcare and Medtronic. Evgenij V. Potapov reports receiving grants from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving consulting fees from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving payment for lectures from Abiomed, Abbott, Recovery Therapeutics, and Medtronic. Evgenij V. Potapov reports receiving support for attending meetings from Abiomed, Abbott, and Medtronic. Vivek Rao reports receiving consulting fees from Abbott and Medtronic. Vivek Rao reports receiving payment for lectures from Abbott. Vivek Rao reports holding Medtronic stock. Bastian Schmack reports receiving consulting fees as a medical advisor from Adjucor GmbH, and payment or honoraria for proctoring from Johnson & Johnson MedTech, Berlin Heart GmbH, and Abbott Inc. Scott Silvestry reports receiving consulting fees from Abbott and Abiomed. Scott Silvestry reports receiving payment for lectures from Abbott and Abiomed. Scott Silvestry reports receiving payment for expert testimony from Abbott. Scott Silvestry reports participation on an advisory board for Carmat. Edward Soltetz reports receiving payment from Abiomed for speaking and training. Edward Soltetz reports being the national Co-PI for the IMPACT Trial, which is sponsored by Abiomed. Hiroo Takayama reports consulting fees from Artivion and Edwards (payments made to the institution). Joseph Tonna reports receiving grants from NIH, NHLBI, and ROI. Joseph Tonna reports being the Registry Chair of ELSO. Glenn Whitman reports receiving consulting fees from Cellphire LLC for a national RCT on cryopreserved platelets in Cardiac Surgery. Glenn Whitman reports being in the design phase of a patent, 50% owned, for a Safe Cannulation Assist Device. Dominik Wiedemann reports receiving payment for lectures from Xenios/Fresenius, Abiomed, Edwards Lifesciences, and Abbott. Dominik Wiedemann reports receiving support for attending meetings from Xenios/Fresenius, Abiomed, and Abbott. Dominik Wiedemann reports participating on an advisory board for Xenios/Fresenius as a scientific adviser. Daniel Zimpfer reports receiving grants or contracts from Edwards, Abbott, Berlin Heart, Corcym, Abiomed, Atricure. Daniel Zimpfer reports receiving consulting fees from Abiomed and Abbott. Daniel Zimpfer reports receiving payment or honoraria for lectures from Edwards, Corcym, Abbott, Abiomed, Berlin Heart, and Atricure. Daniel Zimpfer reports receiving support for attending meetings from Medtronic, Edwards, Novomed, Fa. Duschek, Biotronik, Bimed, Abbott, SJM, St. Jude Medical, Maquet, Heartware, Sorin, Janssen, Johnson, J.C General, B. Braun, Boston, Baxter, Euromed, Getinge, MIN Medical Innovation, Actelion, Cryolife, Vascutek, HSEC, Neucomed, Biomedica, Hirmann, Artivion, Takeda, C. Brady, Atricure, Cytosorbents, Covidien, Guidant, ATS, LSI Solutions, B\u20ACock, Nycomed, Ducest, Pfizer, Comesa, Tyco, Santec, W. L. Gore, MACs Medical, Philips, Intramed, and Roche. The other authors have no conflicts of interest to disclose.
Publisher Copyright:
Copyright © 2026. Published by Elsevier Inc.
PY - 2026/7
Y1 - 2026/7
N2 - Background Protected cardiac surgery is a proactive strategy that applies temporary mechanical circulatory support to prevent perioperative low cardiac output syndrome in high-risk cardiac surgery. Rather than escalating vasoactive agents after hemodynamic decline, the approach emphasizes early identification of physiologic vulnerability and timely initiation of support. Methods We conducted a structured literature review of peer-reviewed studies published from 2000 to 2024 on temporary mechanical circulatory support in adult cardiac surgery. There were 52 studies selected based on relevance to early or prophylactic support, timing of initiation, risk stratification, and systems of care. Clinical insights from multidisciplinary experts also informed the review framework. Results Inotropic escalation after hemodynamic deterioration is consistently associated with poor outcomes. High pharmacologic requirements and severe metabolic derangements predict very high mortality, whereas conventional risk scores often fail to identify vulnerable patients. In contrast, early initiation of mechanical support has been associated with lower in-hospital mortality, reduced dependence on vasoactive agents, and improved recovery. Physiologic markers, such as filling pressures and lactate levels, may provide earlier signals of circulatory decline. Effective implementation also requires institutional coordination, team-based planning, and regional referral systems. Conclusions Protected cardiac surgery reframes success in high-risk cardiac surgery by focusing on recovery rather than survival alone. It integrates physiology-guided support with structured planning and system-level readiness to improve outcomes in vulnerable surgical populations.
AB - Background Protected cardiac surgery is a proactive strategy that applies temporary mechanical circulatory support to prevent perioperative low cardiac output syndrome in high-risk cardiac surgery. Rather than escalating vasoactive agents after hemodynamic decline, the approach emphasizes early identification of physiologic vulnerability and timely initiation of support. Methods We conducted a structured literature review of peer-reviewed studies published from 2000 to 2024 on temporary mechanical circulatory support in adult cardiac surgery. There were 52 studies selected based on relevance to early or prophylactic support, timing of initiation, risk stratification, and systems of care. Clinical insights from multidisciplinary experts also informed the review framework. Results Inotropic escalation after hemodynamic deterioration is consistently associated with poor outcomes. High pharmacologic requirements and severe metabolic derangements predict very high mortality, whereas conventional risk scores often fail to identify vulnerable patients. In contrast, early initiation of mechanical support has been associated with lower in-hospital mortality, reduced dependence on vasoactive agents, and improved recovery. Physiologic markers, such as filling pressures and lactate levels, may provide earlier signals of circulatory decline. Effective implementation also requires institutional coordination, team-based planning, and regional referral systems. Conclusions Protected cardiac surgery reframes success in high-risk cardiac surgery by focusing on recovery rather than survival alone. It integrates physiology-guided support with structured planning and system-level readiness to improve outcomes in vulnerable surgical populations.
U2 - 10.1016/j.athoracsur.2025.12.032
DO - 10.1016/j.athoracsur.2025.12.032
M3 - (Systematic) Review article
SN - 0003-4975
VL - 122
SP - 22
EP - 32
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 1
ER -